Endometrial carcinoma with yolk sac tumor-like differentiation and elevated serum $\beta$-hCG: a case report and literature review

Mingliang Ji$^1$
Yan Lu$^1$
Lina Guo$^2$
Fengzhi Feng$^1$
Xirun Wan$^1$
Yang Xiang$^1$

$^1$Department of Obstetrics and Gynecology, $^2$Department of Pathology, Peking Union Medical College Hospital, Beijing, People’s Republic of China

Abstract: Endometrial carcinoma with a germ cell tumor component is a rare event. Here we report a uterine neoplasm with a unique combination of endometrioid adenocarcinoma and mixed germ cell malignant elements. A 28-year-old woman with abnormal vaginal bleeding, an abdominal mass, and elevated alfa-fetoprotein and beta-human chorionic gonadotropin ($\beta$-hCG) levels had a history of biopsy of an omental mass and chemotherapy in another hospital one month before her referral to our department. Histologic examination of the mass removed from the omentum revealed an endometrioid adenocarcinoma with yolk sac tumor-like differentiation. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, and removal of metastatic disease were then undertaken at our hospital. Postoperative chemotherapy was given. Eight months postoperatively, serum alfa-fetoprotein and $\beta$-hCG rose again. Cases with primary yolk sac tumors of the endometrium or endometrial carcinoma with trophoblastic differentiation in the literature were reviewed.

Keywords: endometrial carcinoma, yolk sac tumor, trophoblastic differentiation

Introduction

Yolk sac tumors, also known as endodermal sinus tumors, and trophoblastic neoplasms are both malignant germ cell tumors. Producing alfa-fetoprotein and human chorionic gonadotropin (hCG), respectively, yolk sac tumors and trophoblastic neoplasms are strongly suggested by elevated serum alfa-fetoprotein and hCG levels.

Primary yolk sac tumors of the endometrium are extremely rare; to our knowledge, only nine cases have been reported in the literature, among which only two cases are in coexistence with endometrial carcinomas. Endometrial carcinomas with trophoblastic differentiation are also very rare, with only 17 cases in the literature. Despite being uncommon, such cases have a distinct prognosis from pure endometrial adenocarcinoma. These two groups of cases do not share an intersection set. However, we report a case of endometrial carcinoma with yolk sac tumor-like differentiation, as well as elevated serum level of the beta-subunit of hCG ($\beta$-hCG), which suggests trophoblastic differentiation although there is a lack of histologic evidence. A dramatic postoperative reduction of $\beta$-hCG further supports the existence of a trophoblastic component.

Case report

A 28-year-old, nulligravid, married Chinese woman presented in December 2010 with a 14-month history of abnormal vaginal bleeding. The patient had been on barrier contraception, and to her knowledge had never been pregnant. Past medical history...
included epilepsy and hypothyroidism due to thyroidec-
tomy. In October 2010, a diagnostic curettage speci-
men revealed endometrial adenocarcinoma with glandular squamous meta-
plasia, and an exploratory laparotomy was performed in a 
local hospital. A large omental mass and diffuse miliary nod-
ules in the pelvic peritoneum made exposure of the surgical 
field difficult, so biopsy of the mass and peritoneum only was 
performed and histologic examination showed endometrial adenocarcinoma with yolk sac tumor-like differentia-
tion. Chemotherapy, including intravenous paclitaxel 120 mg, 
adriamycin 60 mg, and intraperitoneal cisplatin 150 mg 
for one course, was administered at the local hospital. The 
patient was then referred to our hospital, where laboratory 
tests showed serum alfa-fetoprotein level of 1,522 ng/mL 
(normal value ≤20 ng/mL), β-hCG 518.9 mIU/mL (normal 
value ≤5 mIU/mL, chemiluminescent technology, Advia 
Centaur™ XP immunoassay system, Siemens, Erlangen, 
Germany), and CA 125 129 U/mL (normal value ≤35 U/mL).
A chest computed tomography scan was negative.

The patient underwent cytoreductive surgery, including 
total abdominal hysterectomy, bilateral salpingoo-
oophorectomy with pelvic lymphadenectomy, omentectomy, 
appendectomy, partial sigmoidectomy with anastomosis, and 
resection of abdominal and pelvic metastases, without resid-
ual visible metastases. The uterus measured 10 × 8 × 5 cm 
and the cavity was filled with a cauliflower-like tumor 
measuring 6 × 3 × 2.5 cm and containing areas of ulceration 
(see Figure 1). This solid tumor had a grayish-white cut sur-
face and moderate texture. Histopathologic examination of 
the uterine tumor revealed well to moderately differentia-

ted endometrial adenocarcinoma with yolk sac tumor-like 
differentiation intraendometrially, with a close transition 
between the two components (Figure 2). No trophoblastic 
component was found. The metastases were identical to the 
primary lesion on histology. The myometrium, cervix, appen-
dix, bilateral adnexa, and iliac lymph nodes were negative 
for tumor. Periodic-acid Schiff stain was positive in yolk 
sac tumor cells. Immunohistochemical analysis revealed 
that both endometrial adenocarcinoma and yolk sac tumor 
components were positive for AE1/AE3. The yolk sac tumor 
component was strongly positive for alfa-fetoprotein, while 
the endometrial adenocarcinoma was relatively negative 
(Figure 3). The endometrial adenocarcinoma component 
was positive for EMA, CA125, and CK7, suggesting epi-
thelial neoplasms. There was focal positive staining for p53.
Estrogen receptor and progesterone receptor status were both 
negative, as were hCG and β-hCG.

Figure 2 Mixed components: a close transition from the endometrial adenocarcino-
ma to the yolk sac tumor areas (hematoxylin and eosin, 100×).

Figure 3 Immunohistochemical staining results for alfa-fetoprotein confirm the 
existence of two components of endometrial adenocarcinoma and yolk sac tumor.
### Table 1: Cases of primary yolk sac tumors of the endometrium

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Case</th>
<th>Age (years)</th>
<th>Gravida and para</th>
<th>Serum AFP level</th>
<th>Histopathology</th>
<th>Metastasis</th>
<th>Surgery</th>
<th>Chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pileri et al</td>
<td>1980</td>
<td>1</td>
<td>28</td>
<td>2/2</td>
<td>380 ng/mL</td>
<td>YST</td>
<td>Liver, pelvic LNs</td>
<td>TAH, BSO</td>
<td>VCR, vinblastine, CPA, ADM, MTX, 5-FU, medroxyprogesterone acetate</td>
</tr>
<tr>
<td>Clement et al</td>
<td>1988</td>
<td>2</td>
<td>24</td>
<td>&gt;0/&gt;0</td>
<td>3,600 ng/mL</td>
<td>YST</td>
<td>Umbilicus</td>
<td>Supracervical HYS, BSO</td>
<td>TAH, BSO, OMT</td>
</tr>
<tr>
<td>Ohta et al</td>
<td>1988</td>
<td>3</td>
<td>27</td>
<td>0/0</td>
<td>1,580 ng/mL</td>
<td>YST</td>
<td>ND</td>
<td>HYS, BSO</td>
<td>VCR, Act-D, CPA</td>
</tr>
<tr>
<td>Joseph et al</td>
<td>1990</td>
<td>4</td>
<td>42</td>
<td>5/5</td>
<td>18,530 ng/mL</td>
<td>YST</td>
<td>None</td>
<td>TAH, BSO</td>
<td>Vinblastine, BLM, CDDP</td>
</tr>
<tr>
<td>Spatz et al</td>
<td>1997</td>
<td>5</td>
<td>49</td>
<td>1/1</td>
<td>Normal</td>
<td>YST</td>
<td>None</td>
<td>TAH, BSO, LD</td>
<td>Refused</td>
</tr>
<tr>
<td>Patner et al</td>
<td>2000</td>
<td>6</td>
<td>59</td>
<td>3/3</td>
<td>27,670 U/mL</td>
<td>Adenocarcinoma, YST</td>
<td>Liver, diaphragm</td>
<td>TAH, BSO, LD, OMT</td>
<td>BEP (BLM, VP-16, CDDP), EP (VP-16, CDDP)</td>
</tr>
<tr>
<td>Oguri et al</td>
<td>2006</td>
<td>7</td>
<td>65</td>
<td>ND</td>
<td>2,306 ng/mL</td>
<td>MMMT containing adenocarcinoma, stromal sarcoma, YST</td>
<td>LNs</td>
<td>Modified radical HYS, BSO, LD</td>
<td>PTX, CBDCA</td>
</tr>
<tr>
<td>Rossi et al</td>
<td>2011</td>
<td>8</td>
<td>30</td>
<td>ND</td>
<td>1,762 ng/mL</td>
<td>YST</td>
<td>None</td>
<td>TAH</td>
<td>BEP (BLM, VP-16, CDDP)</td>
</tr>
<tr>
<td>Wang et al</td>
<td>2011</td>
<td>9</td>
<td>29</td>
<td>2/1</td>
<td>3,593.4 ng/mL</td>
<td>YST</td>
<td>None</td>
<td>Modified HYS with left adnexa resection, LD</td>
<td>VP-16, CBDCA, BLM</td>
</tr>
<tr>
<td>Present</td>
<td>2011</td>
<td>10</td>
<td>28</td>
<td>0/0</td>
<td>1,522 ng/mL</td>
<td>Adenocarcinoma, YST</td>
<td>Peritoneum</td>
<td>TAH, BSO, OMT, LD, appendectomy, partial resection of the sigmoid colon with anastomosis</td>
<td>PTX, ADM, CDDP, CBDCA, MTX, Act-D, VP-16, BLM, pingamyacin, VCR, FUDR, oxaliplatin, CPA</td>
</tr>
</tbody>
</table>

**Follow-up time (months):**
- 8 DOD
- 24 DOD
- 14 NED
- 24 NED
- 20 NED
- 19 AWD
- 72 NED
- 39 NED
- 10 AWD

**Status at last follow-up:**
- DOD
- NED
- aWD
- ND
- aWD

**Abbreviations:**
- AFP, α-fetoprotein
- YST, yolk sac tumor
- LN, lymph node
- TAH, total abdominal hysterectomy
- BSO, bilateral salpingo-oophorectomy
- VCR, vincristine
- CPA, cyclophosphamide
- ADM, Adriamycin
- MTX, methotrexate
- 5-FU, 5-fluorouracil
- DOD, dead from the disease
- HYS, hysterectomy
- Act-D, actinomycin-D
- OMT, omentectomy
- ND, not described
- NED, no evidence of the disease
- MMMT, malignant mullerian mixed tumor
- VP-16, etoposide
- AWD, alive with disease
- PTX, paclitaxel
- CBDCA, carboplatin
- FUDR, 5-fluoro-2-deoxy-β-uridine.
Two days after surgery, serum alpha-fetoprotein and beta-hCG levels decreased dramatically to 166.4 ng/mL and 13.7 mIU/mL, respectively, and the CA125 level dropped into the normal range. Six courses of intravenous chemotherapy with paclitaxel 175 mg/m² per day followed by carboplatin for an area under the concentration-time curve of 5 mg/mL per minute were administered every 21 days. Serum alpha-fetoprotein dropped to the normal range after three courses, while beta-hCG fluctuated in the range of 5–20 mIU/mL despite two additional courses of chemotherapy with etoposide, methotrexate, actinomycin D, etoposide, and cisplatin followed by two courses with bleomycin, etoposide, and platinum. The persistent slightly elevated beta-hCG was considered due to abnormal pituitary feedback, so chemotherapy

Table 2 Cases of endometrial neoplasm with trophoblastic differentiation

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Case</th>
<th>Age (years)</th>
<th>Gravida and para</th>
<th>Serum (S)/urinary (U) hCG level</th>
<th>Concurrent endometrial tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Civantos and Rywlin</td>
<td>1972</td>
<td>1</td>
<td>87</td>
<td>3/2</td>
<td>U hCG: 1,000 IU/24 hours</td>
<td>SPC</td>
</tr>
<tr>
<td>Savage et al</td>
<td>1987</td>
<td>2</td>
<td>70</td>
<td>1/1</td>
<td>Unmeasured</td>
<td>AD</td>
</tr>
<tr>
<td>Pesce et al</td>
<td>1991</td>
<td>3</td>
<td>78</td>
<td>ND/0</td>
<td>S β-hCG: 19,500 mIU/mL</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>S β-hCG: 3,050 mIU/mL</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>U hCG: 1,000,000 IU/24 hours</td>
<td>AD</td>
</tr>
<tr>
<td>Kalir et al</td>
<td>1995</td>
<td>6</td>
<td>83</td>
<td>0/0</td>
<td>S hCG: &gt;1,00,000 mIU/mL</td>
<td>AD</td>
</tr>
<tr>
<td>Black et al</td>
<td>1998</td>
<td>7</td>
<td>88</td>
<td>ND/1</td>
<td>S hCG: 851 IU/L (estimated postoperatively)</td>
<td>Clear cell AD; focal endometrioid differentiation</td>
</tr>
<tr>
<td>Bradley et al</td>
<td>1998</td>
<td>8</td>
<td>68</td>
<td>4/4</td>
<td>S β-hCG: 95 mIU/mL</td>
<td>AD</td>
</tr>
<tr>
<td>Tunc et al</td>
<td>1998</td>
<td>9</td>
<td>54</td>
<td>6/6</td>
<td>S β-hCG: 5,514 mIU/mL</td>
<td>AD</td>
</tr>
<tr>
<td>Khuu et al</td>
<td>2000</td>
<td>10</td>
<td>71</td>
<td>0/0</td>
<td>S β-hCG: 283 mIU/mL</td>
<td>(Anterior) AD; (posterior) MM MT containing AD</td>
</tr>
<tr>
<td>Nguyen et al</td>
<td>2000</td>
<td>11</td>
<td>34</td>
<td>0/0</td>
<td>S β-hCG: 32,000 mIU/mL</td>
<td>MM MT containing AD, focal clear cell and serous differentiation</td>
</tr>
<tr>
<td>Le Bret et al</td>
<td>2005</td>
<td>12</td>
<td>54</td>
<td>4/1</td>
<td>S β-hCG: 13,87,205 IU/L</td>
<td>AD</td>
</tr>
<tr>
<td>Horn et al</td>
<td>2006</td>
<td>13</td>
<td>61</td>
<td>3/3</td>
<td>S β-hCG: 2,25,000 IU/L</td>
<td>SPC</td>
</tr>
<tr>
<td>Akbulut et al</td>
<td>2008</td>
<td>14</td>
<td>42</td>
<td>ND/ND</td>
<td>S β-hCG: 1,74 mIU/mL</td>
<td>AD</td>
</tr>
<tr>
<td>Yamada et al</td>
<td>2008</td>
<td>15</td>
<td>58</td>
<td>1/1</td>
<td>S β-hCG: 38 ng/mL</td>
<td>AD</td>
</tr>
<tr>
<td>Olson et al</td>
<td>2011</td>
<td>16</td>
<td>68</td>
<td>6/4</td>
<td>ND</td>
<td>AD</td>
</tr>
<tr>
<td>Wakahashi et al</td>
<td>2012</td>
<td>17</td>
<td>85</td>
<td>5/2</td>
<td>S β-hCG: 8.0 ng/mL (normal, &lt;0.1 ng/mL)</td>
<td>AD with squamous differentiation</td>
</tr>
<tr>
<td>Present</td>
<td>2018</td>
<td>18</td>
<td>28</td>
<td>0/0</td>
<td>S β-hCG: 518.9 mIU/mL</td>
<td>AD, YST</td>
</tr>
</tbody>
</table>

Abbreviations: hCG, human chorionic gonadotropin; SPC, serous papillary carcinoma; ND, not described; AD, adenocarcinoma; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; S-FU, 5-fluorouracil; ADM, adriamycin; DOD, dead of the disease; LN, lymph node; CDDP, cisplatin; BLM, bleomycin; VCR, vincristine; MTX, methotrexate; VP-16, etoposide; AWD, alive with the disease; Gy, gray; UTI, urinary tract infection; OMT, omentectomy; LD, lymphadenectomy; PTX, paclitaxel; CBDC, carboplatin; NED, no evidence of the disease; ACT-D, actinomycin-D; MMMT, malignant mullerian mixed tumor; CPA, cyclophosphamide; THP, herarubicin; YST, yolk sac tumor; FUDR, 5-fluoro-2′-deoxy-β-uridine.
was stopped. Unfortunately, β-hCG and alfa-fetoprotein rose again 2–3 months later. Despite salvage chemotherapy with two cycles of flouxuridine, dactinomycin, etoposide, and vincristine, serum alfa-fetoprotein reached 311.1 ng/mL and β-hCG reached 2,716.5 mIU/mL. After the final course with oxaliplatin 200 mg and cyclophosphamide 800 mg, the patient abandoned further treatment and was lost to follow-up.

Discussion
Here we report a case of endometrial carcinoma with yolk sac tumor-like differentiation as well as elevated serum β-hCG level suggesting trophoblastic differentiation although there was a lack of histologic evidence. Yolk sac tumors and trophoblastic neoplasms are both malignant germ cell tumors, and when found simultaneously, mixed germ cell

<table>
<thead>
<tr>
<th>Metastasis</th>
<th>Surgery</th>
<th>Chemotherapy</th>
<th>Radiotherapy</th>
<th>Follow-up time (mo)</th>
<th>Status at last follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>ND</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Liver, kidneys, lungs,</td>
<td>TAH, BSO</td>
<td>Medroxyprogesterone, S-FU, ADM, megestrol acetate</td>
<td>–</td>
<td>14</td>
<td>DOD</td>
</tr>
<tr>
<td>brain, peritoneum</td>
<td></td>
<td>CDDP, BLM, oncovin (VCR)</td>
<td>–</td>
<td>1.5</td>
<td>DOD</td>
</tr>
<tr>
<td>LNs</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Lungs</td>
<td>TAH</td>
<td>MTX; VP-16, BLM, CDDP</td>
<td>–</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Peritoneum, lungs, liver</td>
<td>TAH, BSO</td>
<td>–</td>
<td>–</td>
<td>14</td>
<td>DOD</td>
</tr>
<tr>
<td>Lungs</td>
<td>TAH, BSO</td>
<td>CDDP, VP-16</td>
<td>–</td>
<td>1</td>
<td>AWD</td>
</tr>
<tr>
<td>None</td>
<td>TAH, BSO</td>
<td>–</td>
<td>50.4 Gy on pelvis</td>
<td>18</td>
<td>Died from UTI</td>
</tr>
<tr>
<td>LNs</td>
<td>TAH, BSO, OMT, LD</td>
<td>Megestrol acetate; PTX, CBDDCA</td>
<td>–</td>
<td>16</td>
<td>NED</td>
</tr>
<tr>
<td>Retroperitoneal mass</td>
<td>TAH, BSO</td>
<td>MTX, CPA, Act-D, VP-16, folicin acid</td>
<td>–</td>
<td>24</td>
<td>DOD</td>
</tr>
<tr>
<td>–</td>
<td>TAH, BSO, LD</td>
<td>–</td>
<td>–</td>
<td>8</td>
<td>NED</td>
</tr>
<tr>
<td>Lungs, brain, LNs</td>
<td>TAH, BSO, OMT, LD</td>
<td>PEB (BLM, VP-16, CDDP), EMA/CO (VP-16, MTX, Act-D, CPA, VCR), CDDP, PTX</td>
<td>44 Gy on brain</td>
<td>7</td>
<td>DOD</td>
</tr>
<tr>
<td>Lungs</td>
<td>Colpotomyectomy, LD</td>
<td>VP-16, CDDP</td>
<td>45 Gy on pelvis</td>
<td>18</td>
<td>NED</td>
</tr>
<tr>
<td>Lungs</td>
<td>TAH, BSO, LD</td>
<td>MTX, EMA/CO (VP-16, MTX, Act-D, CPA, VCR)</td>
<td>–</td>
<td>3</td>
<td>DOD</td>
</tr>
<tr>
<td>None</td>
<td>TAH, BSO, appendectomy, OMT, LD</td>
<td>–</td>
<td>–</td>
<td>6</td>
<td>NED</td>
</tr>
<tr>
<td>Vaginal cuff</td>
<td>TAH, BSO, LD</td>
<td>CTP (CBDDCA, THP, CPA); EMA/CO (VP-16, MTX, Act-D, CPA, VCR)</td>
<td>–</td>
<td>50</td>
<td>NED</td>
</tr>
<tr>
<td>Axillary LN</td>
<td>TAH, BSO</td>
<td>ND</td>
<td>–</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Peritoneum;</td>
<td>TAH, BSO</td>
<td>–</td>
<td>–</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Douglas pouch</td>
<td>TAH, BSO</td>
<td>PTX, ADM, CDDP, CBDDCA, MTX, Act-D, VP-16, BLM, pingyangmycin, VCR, FUHR, oxaliplatin, CPA</td>
<td>–</td>
<td>10</td>
<td>AWD</td>
</tr>
</tbody>
</table>

Abbreviations:
- THP, herarubicin
- YST, yolk sac tumor
- FUDR, 5-fluoro-
- pTX, paclitaxel
- CBDCa, carboplatin
- NeD, no evidence of the disease
- act-D, actinomycin-D
- MMMT, malignant mullerian mixed tumor
- Cpa, cyclophosphamide
- VCr, vincristine
- MTX, methotrexate
- Vp-16, etoposide
- aWD, alive with the disease
- Gy, gray
- UTI, urinary tract infection
- OMT, omentectomy
- LD, lymphadenectomy
tumor is diagnosed, and usually within the gonads.\textsuperscript{28} Primary extragonadal concurrent yolk sac tumors and trophoblastic neoplasms are extremely rare, but have been known to occur in the thyroid.\textsuperscript{29} Barrett’s esophagus,\textsuperscript{30} and in gastric\textsuperscript{31} and colon carcinoma.\textsuperscript{32} The histogenetic mechanism for primary extragonadal germ cell tumors remains controversial.\textsuperscript{7} The close transition from the endometrioid adenocarcinoma to the yolk sac tumor areas (Figure 2) in the present case supports an origin involving aberrant differentiation of somatic cells. Mixed tumors with a germ cell tumor component usually manifest as tumors in corresponding organs; for instance the present case had a medical history of abnormal vaginal bleeding of 14 months’ duration, which unfortunately was not paid enough attention. Unlike typical endometrial carcinoma, she was young and presented with peritoneal metastasis without myometrial infiltration or lymphadenopathy. Hence, histopathologic examination of specimens from diagnostic curettage and exploratory laparotomy are of great clinical importance in such circumstances.

Primary yolk sac tumors of the endometrium are extremely rare. To our knowledge, only nine cases have been reported in the literature (Table 1),\textsuperscript{1–9} among which seven cases are pure yolk sac tumors and only two cases\textsuperscript{8,7} are in coexistence with endometrial carcinoma. All the patients presented with a medical history of abnormal vaginal bleeding and elevated serum alfa-fetoprotein levels before or immediately after surgery. Extragonadal germ cell tumors are diagnosed histopathologically. Yolk sac tumor presents variously under the microscope, and occasionally there is confusion in differentiating a microcystic or endodermal sinus-like structure from a clear cell uterine carcinoma and a papillary structure from uterine serous papillary carcinoma. In addition to morphologic differences, immunohistochemical staining is helpful. Yolk sac tumors are strongly positive for alfa-fetoprotein. In addition, serum alfa-fetoprotein determinations are important in the diagnosis of yolk sac tumors and monitoring metastasis or recurrence after therapy. Most of the reviewed cases experienced a reduction in serum alfa-fetoprotein after surgery and adjuvant therapy, as did our patient.

Yolk sac tumors usually occur in the gonads of young people.\textsuperscript{1} In the previously published literature, cases with pure yolk sac tumors are younger (age range 27–49 years, mean 32.7 years) than those with mixed tumors (age range 59–65 years, mean 62 years). In the seven patients with pure yolk sac tumors, five\textsuperscript{5–8,9} presented no metastasis (or not described) and no evidence of disease at last follow-up more than one year (6 year at most) after diagnosis. Among these five, two cases\textsuperscript{8,9} had a unilateral ovary or bilateral ovaries retained after surgery because they were young women, indicating a more favorable prognosis. In contrast with these cases, those with endometrial neoplasms with yolk sac tumor-like differentiation were all postmenopausal women, and presented with early metastasis to the liver, diaphragm, or abdominal lymph nodes. This second group of cases tends to have a worse prognosis. The case reported by Patsner\textsuperscript{6} used a potential carcinogen (tamoxifen for prior breast cancer) and the tumor metastasized 19 months after diagnosis despite two surgeries and administration of combined chemotherapy and radiotherapy. The different components of the tumor have a transition zone, so erroneous differentiation of somatic cells was proposed as the histogenetic mechanism of the tumor cells, ie, the yolk sac tumor cells were derived from dedifferentiation or retrodifferentiation of somatic endometrial (tumor) cells. The present case had concurrent endometrioid adenocarcinoma and yolk sac tumor components in both primary and metastatic tumors, and metastasis occurred early. Despite multiple courses and regimens of chemotherapy, alfa-fetoprotein rose again 8 months postoperatively. These clinical and pathologic features strongly resemble the cases in the latter group mentioned above, except for the very young age of 28 years.

The present self-reported nulligravid case had elevated serum β-hCG level during her entire medical course, but no trophoblastic differentiation was observed under the microscope. Grenache et al\textsuperscript{13} reported a similar case of endometrial adenocarcinoma without trophoblastic differentiation and with an elevated serum free β-hCG and no evidence of pregnancy. In their case, endometrial adenocarcinoma cells showed hCG immunoreactivity and were believed to produce free β-hCG. In the present case, however, the decrease in β-hCG following surgery and chemotherapy excluded the possibility of phantom β-hCG or β-hCG elevation associated with the testing method used. Given that the tumor cells seen were negative for hCG and β-hCG by immunohistochemical analysis, the authors believe that a trophoblastic component did exist, and the negative histology findings might be due to the chemotherapy before admission, and failure to get the positive section in pathological slice-making.

Endometrial neoplasms with trophoblastic differentiation are also very rare, with only 17 cases reported in the literature (Table 2).\textsuperscript{10–24} These 17 patients are relatively older (age range 34–88 years, mean 65.4 years). All cases, including the present one, presented with abnormal genital bleeding except for one without description, and elevated serum or urinary
β-hCG before or shortly after therapy, with a median serum β-hCG level of 3,050 mIU/mL, except one case with normal serum β-hCG first measured after histologic diagnosis of surgical specimens. 21 Most of the cases had been pregnant, so gestational trophoblastic neoplasms could not be excluded completely. However, Olson et al 22 reported a case with clonal evolution from endometrioid carcinoma to trophoblastic tumor proven by morphologic and molecular genetic analysis, suggesting great utility of this method. Endometrioid adenocarcinoma is the most frequently reported histologic type in the predominant component of the concurrent tumor, occurring in 12 of the reported cases, with serous papillary carcinoma in two cases and clear cell carcinoma in one case. Khue et al 17 and Nguyen et al 18 reported two cases of malignant Müllerian mixed tumor containing an endometrioid adenocarcinomatous component with trophoblastic differentiation as well as a sarcomatous component. The median follow-up duration was 11 months, and at last follow-up, seven cases had died (follow-up 1.5–24 months), two were alive with disease (1 and 5 months), and five with relatively low initial serum β-hCG (median 283 mIU/mL) were alive without evidence of disease (6–50 months).

Horn et al 20 proposed two prognostically relevant types of endometrial carcinoma containing trophoblastic differentiation. One type presents with only a few syncytiotrophoblastic-like giant cells and the other with a notable extension of trophoblastic differentiation, resembling a choriocarcinoma. The latter type is associated with strongly elevated β-hCG, early metastasis, and often a fatal course. The present case presented with no observable trophoblastic cells and a moderately elevated β-hCG at admission, suggesting a more favorable prognosis according to Horn’s proposition. However, despite the rapid decrease in β-hCG after hysterectomy, it remained slightly and persistently elevated and finally rose again to 2,716.5 mIU/mL. The patient was lost to follow-up 10 months after diagnosis, implying an unfavorable outcome.

**Conclusion**

To the author’s knowledge, endometrial adenocarcinoma associated with both yolk sac tumor-like differentiation and an elevated serum β-hCG level has never been reported in the literature. We present such a case and share our experiences in treatment. Unlike the reviewed cases of endometrial adenocarcinoma with a single germ cell tumor component, our patient was very young and presented with peritoneal metastasis early but without myometrial infiltration or lymphadenopathy. The histology of the metastases was identical to that of the primary tumor, with mixed components. The cytoreductive surgery and chemotherapy tend to show an effective immediate efficacy. The choice of subsequent chemotherapies was based on the major tumor component at each follow-up. However, the disease progressed rapidly and was resistant to salvage chemotherapy. Because medical history, gynecologic examination, and imaging results contribute little to early recognition of extragonadal germ cell tumors, histopathologic examination of specimens from diagnostic curettage and exploratory laparotomy are of great clinical significance in such conditions. Once diagnosed, serum alfa-fetoprotein and β-hCG determinations are important in monitoring metastasis or recurrence. The histogenetic mechanism is unclear, and further investigations with molecular genetic analysis are required.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


